Acquired angioedema. Case report
Keywords:
angioedema, bradykinin, treatmentAbstract
Introduction: acquired angioedema is a rare disease. It is classified as hereditary and acquired. The causes are varied, they can be secondary to autoimmune diseases, lymphoproliferative syndromes and other neoplasms. This disease occurs through a chemical mediator. Bradykinin explains all the phenomena that occur in a patient with hereditary and acquired angioedema. The treatment consists of modern drugs that are in development. Case report: the patient was admitted with face, neck and trunk edema and showed refractoriness to conventional therapy. Plasma due to drug deficiencies was used for its remission and clinical stability was achieved. Conclusions: in a patient with resistant conventional therapy angioedema, without associated urticaria nor other relatives in the same state, it must think about acquired angioedema.Downloads
References
1. Fonseca Aizpuru EM, Rodríguez Ávila EE, Arias Miranda I, Nuño Mateo FJ. Angioedema hereditario y adquirido: características clínicas de ocho pacientes y revisión de la literatura. Rev Clin Española [Internet]. 2009 Aug [citado 8 Feb 2018];209(7):332-336. Disponible en: http://www.sciencedirect.com/science/article/pii/s001425650971817X
2. Bouillet L. Angioedemas hereditarios y adquiridos. Dermatosis de los estados inflamatorios exceptuando los eccemas hereditarios y adquiridos. EMC-Dermatología [Internet]. 2016 Mar [citado 8 Feb 2018];50(1):1-6. Disponible en: https://www.sciencedirect.com/science/article/pii/S1761289616763345?via%3Dihub
3. Lara-Jiménez MA, Ruiz-Riverab L, Magro-Checac C. Angioedema adquirido por déficit de C1 inhibidor secundario a linfoma B esplénico de la zona marginal. Rev Clin Esp [Internet]. 2014 Dic [citado 8 Feb 2018];214(9):e107-e109. Disponible en: https://www.sciencedirect.com/science/article/pii/S0014256514002422?via%3Dihub
4. Longhurst H, Zanichelli A, Caballero T, Bouillet L, Aberer W, Fabien V, et al. The Icatibant Outcome Survey: Observational data in patients with angioedema due to acquired C1 inhibitor (C1-inh) Deficiency. Journal of Allergy and Clinical Immunology [Internet]. 2015 Feb [citado 8 Nov 2017];135(2):279. Disponible en: https://www.jacionline.org/article/S0091-6749%2814%2903631-8/fulltext
5. Angioedema adquirido tipo 2 [Internet]. México: Federación Mexicana de Enfermedades Raras; 2014 [actualizado 2018; citado 8 feb 2018]. Disponible en: http://www.femexer.org/2168/angioedema-adquirido-tipo-2/
6. Soteres D, Jacobson K, Moldovan D, Christensen J, Van Leerberghe A, Wang Y, et al. Pharmacokinetics/pharmacodynamics of C1 inhibitor for prevention of angioedema attacks in children with hereditary angioedema (HAE). Ann Allergy Asthma Immunol [Internet]. 2016 Nov [citado 8 Nov 2017];117(5):47. Disponible en: https://www.annallergy.org/article/S1081-1206(16)30724-4/fulltext
7. Angioedema mediado por bradicinina [Internet].Vienna: 9th European Conference on Rare Diseases and Orphan Products10-12 May 2018; 2017 [actualizado 7 Feb 2018; citado 8 Feb 2018]. Disponible en: https://www.orpha.net/data/patho/Emg/Int/es/AngioedemaBradicinina_ES_es_EMG_ORPHA658.pdf
8. Sanchez J, Mawarl S, Taha H, Nanchal R. Recurrent abdominal pain and hypotension: a rare presentation of acquired angioedema. Chest [Internet]. 2014 Oct [citado 8 Nov 2017];146(4):311. Disponible en: https://journal.chestnet.org/article/S0012-3692%2816%2949569-3/fulltext
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms:
- Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
- Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
- Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).